

DMD #75358

**Title page**

**Absorption, distribution, metabolism and excretion of the oral prostaglandin D2  
receptor 2 (DP<sub>2</sub>) antagonist fevipiprant (QAW039) in healthy volunteers and in  
vitro**

David Pearson, H. Markus Weiss, Yi Jin, Jan Jaap van Lier, Veit J. Erpenbeck, Ulrike Glaenzel,  
Peter End, Ralph Woessner, Fabian Eggimann, Gian Camenisch.

Novartis Institutes for Biomedical Research, Novartis Pharma AG, Basel, Switzerland (DP,  
HMW, YJ, VJE, UG, PE, RW, FE, GC), PRA Health Sciences (JJvL)

DMD #75358

## Running Title Page

### Fevipirant ADME in healthy volunteers and in vitro

**Corresponding author:** David Pearson

Pharmacokinetics Sciences, Novartis Institutes for Biomedical Research, Postfach, CH-4002

Basel, Switzerland

Tel: +41799112654

Email: [david.pearson@novartis.com](mailto:david.pearson@novartis.com)

**Number of text pages:** 23

**Number of tables:** 5

**Number of figures:** 5

**Number of references:** 29

**Number of words in the Abstract:** 220

**Number of words in the Introduction:** 406

**Number of words in the Discussion:** 1466

**Abbreviations:** ADME, absorption, distribution, metabolism, and excretion; AE, adverse event;  $Ae_{0-240\text{h}}$ , amount of drug excreted into the urine from time zero to 240 hours post-dose; AG, acyl-glucuronide; AUC, area under the concentration-time curve;  $AUC_{0-t}$ , the area under the concentration-time curve from time zero to t;  $AUC_{inf}$ , the area under the concentration-time curve from time zero to infinity; BMI, body mass index; CL/F, the systemic clearance CL of the drug from the plasma divided by the bioavailability F; CL<sub>r</sub>, renal clearance;  $C_{max}$ , the maximum (peak) plasma or blood drug concentration after single administration; CRTh2, chemoattractant receptor-homologous molecule expressed on T-helper type 2 cells; DDI, drug-drug interaction; DMPK, Drug Metabolism and Pharmacokinetics; DP<sub>2</sub>, prostaglandin D<sub>2</sub> receptor 2; EU,

DMD #75358

European Union; HLM, human liver microsomes; HPLC, high-performance liquid chromatography; IL, Isotope Laboratory; LC-MS/MS, liquid chromatography coupled to tandem mass spectrometry; LSC, liquid scintillation counting; MATE, multidrug and toxin extrusion protein; MDR, multi-drug resistance gene; NOAEL, no observed adverse effect level; OAT, organic anion transporter; OATP, organic anion-transporting polypeptide; OCT, organic cation transporter; PK, pharmacokinetic(s); SEC, size exclusion chromatography; TRD, Technical Research and Development;  $T_{max}$ , the time to reach peak or maximum concentration following drug administration;  $T_{1/2}$ , terminal half-life of elimination; UGT, uridine 5'-diphospho (UDP)-glucuronosyltransferase;  $V_z/F$ , the apparent volume of distribution during the terminal phase divided by the bioavailability F.

DMD #75358

## Abstract

Fevipirant is a novel oral prostaglandin D<sub>2</sub> receptor 2 (DP<sub>2</sub>; also known as CRTh2) antagonist, which is currently in development for the treatment of severe asthma and atopic dermatitis. We investigated the absorption, distribution, metabolism, and excretion properties of fevipirant in healthy subjects after a single 200 mg oral dose of [<sup>14</sup>C]-radiolabeled fevipirant. Fevipirant and metabolites were analyzed by liquid chromatography coupled to tandem mass spectrometry and radioactivity measurements, and mechanistic in vitro studies were performed to investigate clearance pathways and covalent plasma protein binding. Biotransformation of fevipirant involved predominantly an inactive acyl glucuronide (AG) metabolite, which was detected in plasma and excreta, representing 28% of excreted drug-related material. The AG metabolite was found to covalently bind to human plasma proteins, likely albumin; however, in vitro covalent binding to liver protein was negligible. Excretion was predominantly as unchanged fevipirant in urine and feces, indicating clearance by renal and possibly biliary excretion. Fevipirant was found to be a substrate of transporters organic anion transporter 3 (OAT3; renal uptake), multi-drug resistance gene 1 (MDR1; possible biliary excretion), and organic anion-transporting polypeptide 1B3 (OATP1B3; hepatic uptake). Elimination of fevipirant occurs via glucuronidation by several uridine 5'-diphospho glucuronosyltransferase (UGT) enzymes, as well as direct excretion. These parallel elimination pathways result in a low risk of major drug-drug interactions or pharmacogenetic/ethnic variability for this compound.

DMD #75358

## Introduction

The prevalence of allergic diseases is increasing worldwide, with the World Health Organization estimating that 400 million people globally will be asthma sufferers by 2025 (Pawankar, 2014).

In the European Union (EU), 44–76 million individuals of the 217 million EU employees suffer from allergic diseases of the airways or the skin and up to 90% of these individuals are untreated or insufficiently treated (Zuberbier et al., 2014).

Fevipirant (QAW039; [(2-[2-methyl-1-(4-[methylsulfonyl]-2-[trifluoromethyl]benzyl)-1H-pyrrolo(2,3-b)pyridin-3-yl] acetic acid)]) is a potent and highly selective novel antagonist of the human prostaglandin D<sub>2</sub> receptor 2 (DP<sub>2</sub>, also known as CRTh2), which is a class A G protein–coupled receptor involved in the modulation of inflammatory responses (Sykes et al., 2016). DP<sub>2</sub> is also expressed on innate immune cells, such as eosinophils and ILC-2 cells, and plays a role in the pathophysiology of respiratory disease (Townley and Agrawal, 2012; Xue et al., 2014).

Recently, human functional studies across diverse cellular systems have shown that fevipirant shows high potency for competitive inhibition of disease-relevant DP<sub>2</sub>-mediated responses in human cells, such as Th2 cell cytokine production, and eosinophil activation (Sykes et al., 2016). Fevipirant is currently in development as a once-daily oral therapy for respiratory and dermatologic disorders, such as severe asthma and atopic dermatitis (Sykes et al., 2016).

Two Phase 1 studies investigated the pharmacokinetics (PK), safety, and tolerability of fevipirant after single and multiple ascending doses in healthy subjects (Erpenbeck et al., 2016). On administration of single and multiple oral doses, fevipirant peak plasma concentrations were observed 1–3 hours post-dose, and the apparent terminal half-life was approximately 20 hours. Steady state was achieved within four days, with less than two-fold accumulation. An acyl glucuronide (AG) metabolite without DP<sub>2</sub> antagonist activity was detected in plasma. Fevipirant was well-tolerated at single and multiple oral doses up to 500 mg/day (Erpenbeck et al., 2016).

DMD #75358

With any new chemical entities, it is important to identify and quantify all relevant metabolites and elimination pathways, for assessment of possible metabolite pharmacology, safety (FDA, 2008; ICH, 2009; Gao et al., 2013), clearance mechanisms and drug-drug interactions (DDIs) (EMA, 2012; FDA, 2012), including planning of suitable clinical DDI and hepatic/renal impairment studies.

We report the assessment of human absorption, distribution, metabolism, and excretion (ADME) of a single oral 200 mg dose of [<sup>14</sup>C]-fevipiprant in healthy male subjects, as well as identification of enzymes and transporters involved in the human PK of fevipiprant, and characterization of covalent binding to plasma proteins in humans.

DMD #75358

## Materials and Methods

The primary objectives of the clinical ADME study were to identify and quantify fevipiprant and metabolites in plasma and excreta for analysis of absorption, PK, and elimination pathways.

### Study Drug

The parent batch of [<sup>14</sup>C]-radiolabeled fevipiprant was prepared by the Isotope Laboratory (IL), Drug Metabolism and Pharmacokinetics (DMPK), Novartis, Switzerland. This batch was adjusted to a final specific radioactivity of 15.7 kBq/mg by dilution with non-radiolabeled fevipiprant, produced under Good Manufacturing Practice and released for human use by Technical Research and Development (TRD), Novartis. The chemical structure of the compound and the position of the radiolabel are shown in **Figure 1**.

Chemical and radiochemical purity 99.0% (with no single impurity  $\geq$  1%) was verified by high performance liquid chromatography (HPLC) and stability was ascertained from the period from manufacturing to dose administration. The radiolabeled study drug was provided as individually manufactured doses of four 50 mg (monohydrate; 787.5 kBq) [<sup>14</sup>C]-fevipiprant capsules per bottle providing a total radioactive dose of 3.15 MBq (IL and TRD departments, Novartis).

### Chemicals and Standards

Radiolabeled and non-radiolabeled fevipiprant, radiolabeled and non-radiolabeled AG metabolite and non-radiolabeled lactone metabolite were synthesized as described in (Bala et al., 2005) and (Supplemental Data). All other reagents were of analytical grade and obtained from commercial sources.

### Subjects and Study Design

This was an open-label, single-center, single-arm study to investigate the ADME of a single oral dose of 200 mg [<sup>14</sup>C]-fevipiprant in four healthy male subjects. Informed consent was obtained from each subject in writing before any assessment was performed. The study (registered with

DMD #75358

EudraCT as 2011-002842-10) was conducted at PRA International, Early Development Services, Zuidlaren, The Netherlands, from February 17 through March 26, 2012, according to the ethical principles of the Declaration of Helsinki. The study protocol was reviewed by the Independent Ethics Committee of Stichting Beoordeling Ethiek Biomedisch Onderzoek, Assen, The Netherlands.

Subjects were male, aged 18 to 55 years, weighed  $\geq 50$  kg, with a body mass index (BMI) of 18 to 29 kg/m<sup>2</sup>, and could communicate well with the Investigator, and understand and comply with the requirements of the study. The subjects were nonsmokers, had no history of alcoholism or drug abuse, and did not use any prescription drugs or herbal medication within four weeks prior to dosing and/or over-the-counter medication or dietary supplements (vitamins included) within two weeks prior to dosing.

The study consisted of a screening visit (between Day -14 and Day -2), a baseline visit (on Day -1), a single-dose treatment (on Day 1), 240 hours in-house observation period (Days 1–11), optional collections and assessments (at Day 14 and Day 21), and a study Completion Visit (Day 25). Each subject received a single oral [<sup>14</sup>C]-radiolabeled dose of 200 mg fevipiprant (3.15 MBq, 85  $\mu$ Ci), as four 50 mg capsules, in the morning, after an overnight fast of at least 10 hours. Subjects continued to fast for four hours post-dose (water was allowed after two hours).

The radiation exposure was not deemed to pose any relevant health risk to the subjects. Based on human PK data (with non-radiolabeled fevipiprant) and animal mass balance data (with [<sup>14</sup>C]-fevipiprant), the expected effective radiation dose was estimated to be up to 0.87 mSv, lower than the recommended limit of 1 mSv/year defined by the International Commission on Radiological Protection (ICRP, 2007). It was not expected that the clinical and laboratory staff handling the radioactive materials and samples would be exposed to any radiation and associated health risk.



DMD #75358

Safety assessments included the monitoring and recording of all adverse events (AEs), regular checks of routine blood chemistry, hematology and urine values, electrocardiogram recordings, measurements of vital signs, and physical examinations.

#### *Sample Collection and Aliquoting*

Samples of whole blood, urine, and feces were collected over an 11-day period. Part of each whole blood sample was processed to plasma. Each urine and plasma sample was divided into two parts, and one part of each sample was acidified by addition of 1% volume of a 70% lactic acid solution, in order to stabilize the known AG metabolite. Details of sample collection and processing are given in the (Supplemental Data).

#### **Quantification of total radioactivity, fevipiprant and metabolites**

Total radioactivity in blood, non-acidified plasma, non-acidified urine, and feces was measured by liquid scintillation counting (LSC). Concentrations of fevipiprant and AG metabolite in all acidified plasma samples up to 240 hours post-dose and in acidified urine were assessed by a validated specific liquid chromatography (LC)-mass spectrometry (MS)/MS assay. The AG metabolite was quantified as the sum of all isomers formed by acyl glucuronide rearrangement. Fevipiprant and metabolites were analyzed in acidified plasma, acidified urine and feces extract pools of individual subjects by LC-MS/MS, with offline radioactivity detection. Selected plasma samples were analyzed by size exclusion chromatography (SEC), with off-line radioactivity detection. Details of these analytical methods are provided in the (Supplemental Data).

#### **Structural Characterization of Metabolites**

The structural characterization of metabolites in plasma and excreta was carried out by MS/MS analysis after LC separation of analytes (described above).

Single stage and product ion spectra with exact mass measurements were obtained in positive ion mode. The structures of the metabolites were derived from their product ion mass spectra,

DMD #75358

the elemental composition determined by exact mass measurement and comparison with synthetic standards.

### Pharmacokinetic Evaluations

The present study evaluated the following PK parameters, which were determined from blood (total radioactivity), plasma, and urine:  $C_{max}$  (the maximum [peak] plasma or blood drug concentration after single administration [amount  $\times$  volume<sup>-1</sup>]),  $T_{max}$  (the time to reach peak or maximum concentration following drug administration [time]),  $T_{1/2}$  (the elimination half-life associated with the terminal slope [ $\lambda z$ ], respectively, of a semi-logarithmic concentration-time curve [time]),  $AUC_{0-t}$  (the area under the concentration-time curve from time zero to t [amount  $\times$  time  $\times$  volume<sup>-1</sup>]),  $AUC_{inf}$  (the area under the concentration-time curve from time zero to infinity [amount  $\times$  time  $\times$  volume<sup>-1</sup>]),  $CL/F$  (the systemic clearance CL of the drug from the plasma [volume  $\times$  time<sup>-1</sup>] divided by the bioavailability F),  $V_z/F$  (the apparent volume of distribution during the terminal [ $\lambda z$ ] phase divided by the bioavailability F [volume]),  $Ae_{0-240h}$  (amount of drug excreted into the urine from time zero to 240 hours post-dose [% of dose]),  $CL_r$  (renal clearance; calculated as  $Ae_{0-240h}/AUC_{0-240h}$ ). PK parameters were calculated using Phoenix WinNonlin 6.3 with noncompartmental analysis.

### In vitro Investigations

#### *Fevipirant covalent binding assay in microsomes and hepatocytes*

[<sup>14</sup>C]-fevipirant (5  $\mu$ M, 4.9 MBq/mg) was incubated with human liver microsomes (0.5 mg/mL) at 37°C in sodium phosphate buffer (0.1 M, pH 7.4) in the presence of several sets of cofactors (a) glutathione [GSH, 5 mM]; b)  $\beta$ -nicotinamide adenine dinucleotide phosphate [NADPH, 1 mM]; c) NADPH and uridine 5'-diphosphoglucuronic acid [UDPGA, 4 mM]; d) NADPH, UDPGA and GSH). Aliquots were taken after 1 hour and precipitated with 3 volumes of acetonitrile.

DMD #75358

[<sup>14</sup>C]-fevipiprant (10 μM, 4.9 MBq/mg) was incubated with cryopreserved human hepatocytes (0.5x10<sup>6</sup> cells/mL) 37°C, 95% humidity and 5% CO<sub>2</sub>, in Williams E medium. Aliquots were taken after 0, 1.5 and 3 hours, and precipitated with 4 volumes of acetonitrile.

The precipitate obtained from each experiment was filtered and washed extensively with 90% methanol, then the filters were removed and protein precipitate was solubilized in Solvable, then analyzed by LSC. Covalent protein binding was calculated as pmol/mg protein and pmol/10<sup>6</sup> cells for microsomes and hepatocytes, respectively.

#### *Incubations of radiolabeled fevipiprant and AG-metabolite with human plasma*

[<sup>14</sup>C]-fevipiprant (4.9 MBq/mg) and [<sup>14</sup>C]-AG metabolite (3.3 MBq/mg) were each incubated with 1:1 human plasma/PBS at a final concentration of 20 μM at 37°C for 24 hours. Incubation of [<sup>14</sup>C]-AG metabolite at 100 μM, and control incubations without plasma were also performed. During the 20 μM incubations, aliquots were removed, precipitated by addition of 5 volumes of acetonitrile and incubation at 4°C for 60 minutes, and then filtered. Filters were washed with methanol/water (90:10) until eluate contained less than 5 pmol/mL radioactivity, as measured by LSC. Retained radioactivity in the filters was then measured by dissolution of filters in Solvable (Perkin Elmer) at room temperature for 16 hours, followed by addition of HCl (1M, 0.25 mL), then scintillant (Irgasafe plus, Zinsser Analytic, 5 mL) was added and radioactivity was measured by LSC. Retained radioactivity was assumed to be bound to proteins.

Aliquots from 21-hour incubations were further analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE): 5, 10 and 20 μg aliquots were prepared in XT sample buffer (BioRad) supplemented with 10 mM DTT and heated at 95°C for 5 minutes. Subsequently, prepared samples were loaded to a Criterion™ XT precast gradient Midi gel 4-12% Bis Tris (BioRad). The gel was run for 35 minutes at 200 Volt in Mes buffer (BioRad). The gel was blotted to a PVDF membrane (Transblot Turbo, BioRad) and the resulting membrane was exposed for 4 days to a radio imaging plate (Fujifilm, BAS-IP TR 2040) to detect the radio-

DMD #75358

labeled proteins. Molecular weight and intensities of detected bands was measured by labeling the size marker (all blue standard, BioRad) on the membrane with 3H supplemented ink and the analysis tool of the AIDA software (v.4.25One®).

Additionally, aliquots from 21-hour incubations were depleted of albumin and analyzed by SDS-PAGE: 10  $\mu$ L aliquots of 20  $\mu$ M incubations were purified using ProteoExtract Albumin Removal Kit (Calbiochem #122640). Sample aliquots were diluted with albumin Binding Buffer (350  $\mu$ L) and purified according to the kit manual. The volumes of each eluate were reduced to 110  $\mu$ L by centrifuged at 14000  $\times$  g in 30 kDa Amicon spin filters (Millipore). Protein content of the samples was determined using the Protein DC Assay (BioRad) and a BSA standard in PBS. Samples were then analyzed by SDS-PAGE, as described above.

SDS-PAGE gels were additionally analyzed by gel excision and protein characterization, as follows: the radiolabeled band was excised and digested with trypsin, as described in the In-gel tryptic digestion kit (Thermo Scientific) procedure. The bands were first destained, reduced, alkylated, and washed, as recommended in the procedure before digestion. Digestions with trypsin and chymotrypsin were performed in ammonium bicarbonate (500 mM, pH 8) for 24 hours at 37°C. After incubation, incubates were acidified by adding 1% volume of lactic acid (70% in water). Acidified incubates were analyzed by LC-MS/MS with an Acuity I class system (Waters). Samples were injected onto an Acuity BEH130 C18 column (150  $\times$  2.1 mm, 1.7  $\mu$ m particles, Waters) with a corresponding guard column (10  $\times$  2.1 mm), heated to 30°C.

Separation was performed with a gradient of mobile phases formic acid (0.1%; phase A) and acetonitrile (phase B) at a flow rate of 0.2 mL/minute. The gradient was as follows: 0 to 2 minutes: 5% B; 2 to 70 minutes: 5 to 50% B; 70 to 75 minutes: 50 to 75% B; 75 to 76 minutes: 75 to 5% B; 76 to 86 minutes: 5% B. The eluate was directed to an LTQ-Orbitrap XL mass spectrometer (ThermoFisher) for MS/MS analysis. Protein fingerprint analysis was then performed using ProteinProspector MS-Fit software version 2.

DMD #75358

Aliquots from the 24-hour 100  $\mu$ M incubation of the AG-metabolite were analyzed by SEC, as described for plasma samples (Supplemental Data).

#### *Other in vitro methods*

Descriptions of all other in vitro methods are provided in the (Supplemental Data).

### **Demographics**

A total of four male Caucasian subjects were enrolled and all completed the study. Subjects had a mean age of 43.0 years (range: 27–54), weight of 85.6 kg (range: 77.9–93.5), height of 183.3 cm (range: 176–192), and BMI of 25.5 kg/m<sup>2</sup> (range: 23.8–28.3). Only male subjects were selected in order to perform a detailed analysis in a well-defined uniform group, and as the study size is insufficient to make statistical comparisons of sub-populations such as genders. No significant differences in PK or metabolism are known or anticipated between males and females.

DMD #75358

## Results

### Safety and Tolerability Data

Two (50%) of the subjects reported a total of four AEs during the study, which were considered to be mild in severity. There were no serious AEs or discontinuations due to AEs. Two AEs (headache and somnolence) were considered to be treatment-related. No clinically significant abnormalities or changes were observed in clinical laboratory assessments, vital signs, or electrocardiogram parameters.

### Pharmacokinetics of Total Radioactivity, Fevipiprant, and AG metabolite

Key PK variables calculated for total radioactivity, fevipiprant and AG metabolite are summarized in **Table 1** and **Figure 2**. Values for AG metabolite represent the sum of AG metabolite and all isomers formed by acyl glucuronide rearrangement (assigned by comparison with rearrangement products formed from synthetic AG metabolite).

Following oral administration of [<sup>14</sup>C]-fevipiprant, levels of radioactivity in blood and plasma, and levels of fevipiprant and the AG metabolite in plasma, were initially aligned and reached a maximum at approximately 3 hours post-dose. Radioactivity was detectable in blood and plasma for up to 240 hours post-dose, with a mean terminal half-life in plasma of 254 hours (230 hours in blood). Contrastingly, fevipiprant and its major metabolite, the AG metabolite, were only detected in plasma up to 96 and 120 hours post-dose, respectively, with average half-lives of approximately 12 hours. The total exposure ( $AUC_{0-240\text{ h}}$ ) and  $C_{\text{max}}$  of radioactivity in plasma were approximately two-fold higher than observed in blood, indicating that blood radioactivity was almost entirely located in plasma. Inter-subject variability was low to moderate.

### Metabolite Identification and Profiles, and Metabolite Pharmacokinetic Analysis

Plasma, urine and feces extracts were analyzed by LC-MS/MS with radioactivity detection for metabolite identification and profiles. The structures of all identified metabolites could be

DMD #75358

confirmed by comparison of retention time and mass spectral data with synthesized standards, and are given in **Figure 1**. Mass spectral data and representative product ion mass spectra of fevipiprant and metabolites are shown in **Table S1** and **Figure S1** (Supplemental Data). The only abundant metabolite detected was the AG metabolite. A minor lactone metabolite was also identified, likely resulting from oxidative ring-closure of fevipiprant (see discussion section for more detail). The structures of minor components P5.3 and P8.5 could not be determined.

Metabolite profiles were determined after extraction of samples by solid phase extraction. The extraction recoveries of total radioactivity were found to decrease with time post-dose for all subjects. The average percentage of total radioactivity recovery at 2 hours was 92.6%, but at 48 hours was only 11.0%. Due to the low extractable radioactivity in plasma samples at later time points, radiochromatograms were only analyzed up to 12 hours post-dose. Exposure (as  $AUC_{0-12h}$ ) of fevipiprant and its metabolites, based on the radiochromatogram profiles, is shown in **Table 2**. A representative plasma radiochromatogram for one subject is shown in **Figure 3**. The AG metabolite and fevipiprant represented the main proportion of radioactivity in plasma (total 72% of  $[^{14}C]-AUC_{0-12h}$ ) based on radiochromatograms up to 12 hours. However, fevipiprant and the AG metabolite accounted for a much lower proportion of the total plasma  $[^{14}C]-AUC_{0-240h}$  (around 12%) based on LC-MS/MS quantification up to 240 hours (**Table 1**). Correspondingly, the loss of radioactivity observed during sample processing represented a major proportion of radioactivity, amounting to  $26.6 \pm 2.7\%$  of the plasma  $[^{14}C]-AUC_{0-12h}$  and estimated at 87.7% of the plasma  $[^{14}C]-AUC_{0-240h}$  based on LC-MS/MS quantification of fevipiprant and the AG metabolite. To further investigate the loss of radioactivity during sample processing, additional plasma analysis and in vitro experiments were performed (Covalent Binding and Acyl glucuronide Stability Investigations section).

### Excretion of radiolabeled components

DMD #75358

After oral administration of [ $^{14}\text{C}$ ]-fevipiprant,  $42.1 \pm 4.3\%$  of the dose was recovered in urine and  $51.9 \pm 4.8\%$  was recovered in feces over 240 hours post-dose (**Table S2** (Supplemental Data); **Figure 4**), indicating that radioactive drug-related material was primarily excreted via renal and biliary/fecal excretion. The overall recovery of drug-related material was near complete ( $93.9 \pm 2.6\%$ ). The majority of the radioactivity was recovered within 144 hours post-dose, with subsequent samples up to 240 hours containing less than 1% of the dose.

Metabolite profiles were also determined in urine and feces pools (**Figure 3**). Extraction recovery was high for all excreta samples ( $>88\%$ ). Urinary and feces excretion data for fevipiprant and all metabolites based on metabolite profiles, and urinary excretion data for fevipiprant and the AG metabolite based on LC-MS/MS quantification over 240 hours, are presented in **Table 3**. In urine, fevipiprant and AG metabolite were the major components (total approximately 40% of dose). Urinary excretion data for fevipiprant and the AG metabolite over 240 hours were similar to the 0–72 hours values (**Table 3**). In feces, fevipiprant was the major component excreted. Overall, fevipiprant and AG metabolites represented approximately 85% of the dose excreted in urine and feces, and other metabolites were only present in traces.

Based on urinary excretion data for the period 0–240 hours (**Table 3**), the renal clearance of fevipiprant and AG metabolite were calculated to be 8.92 L/h and 7.99 L/h, respectively.

Absorption was estimated to be at least 43.5%, based on the total radioactive dose recovered from urine (42.1%), and the metabolites excreted in feces (approximately 1.4%).

### **Covalent Binding and Acyl glucuronide Stability Investigations**

Due to the observed long retention of radioactivity in plasma and low extractability of plasma samples, we hypothesized that the AG metabolite could covalently bind to plasma proteins (Regan et al., 2010), leading to long-lived radioactive metabolite-protein conjugates, as



DMD #75358

observed for other compounds, such as ibuprofen (Castillo et al., 1995), tolmetin (Zia-Amirhosseini et al., 1994), and bilirubin (Weiss et al., 1983). Additional in vitro experiments were performed to investigate covalent binding. Initially, [<sup>14</sup>C]-fevipiprant was incubated with human liver microsomes (HLM) and human hepatocytes to investigate possible covalent binding of fevipiprant or metabolites to liver proteins mainly via oxidative processes. Additionally, incubations of [<sup>14</sup>C]-fevipiprant and [<sup>14</sup>C]-AG metabolite in human plasma were performed, followed by precipitation and LSC of proteins to identify whether radiolabeled protein conjugates were formed.

When probing for covalent binding of fevipiprant or metabolites to human liver microsomes and hepatocytes in the presence of various cofactors (**Table 4**) only trace levels of covalent binding were observed in comparison to positive control compounds. Additionally, no increase in covalent binding was observed with the addition of glucuronidation cofactor UDPGA, suggesting that covalent binding to liver microsomes associated with the AG metabolite is insignificant.

In incubations with plasma, fevipiprant showed very low covalent binding to human plasma proteins, while the AG metabolite showed 11-fold higher covalent binding after 24 hours incubation (**Figure S2** (Supplemental Data)), indicating that covalent binding in plasma occurs via the AG metabolite rather than the parent compound.

Subsequently, to identify proteins involved in plasma covalent binding gel electrophoresis of the AG metabolite plasma incubate was carried out. Radio-imaging of the resulting gel (**Figure 5A, lanes A1–3**) showed that only one protein of around 68 kDa size was conjugated to the AG metabolite. Peptide fingerprint analysis of the labeled protein band by LC-MS after gel excision and trypsin/chymotrypsin digest identified that the abundant plasma protein human serum albumin was present. Based on this result, gel electrophoresis of AG metabolite plasma incubates after depletion of albumin was also performed. The intensity of the radio-signal

DMD #75358

detected was significantly reduced by albumin depletion of the respective samples (**Figure 5A, lanes B1–3**). These data show that the AG metabolite forms a conjugate with albumin in vitro.

To evaluate whether this in vitro finding corresponds to the in vivo observations, size exclusion chromatography (SEC) of the AG metabolite plasma incubates and of the clinical plasma samples was performed (gel electrophoresis could not be performed on the in vivo samples, due to insufficient sensitivity). SEC of the AG metabolite in vitro incubation showed the presence of fevipirant, AG metabolite, and an earlier eluting peak assigned to a protein conjugate (**Figure 5B**). Analysis of in vivo human plasma samples showed similar profiles (representative samples are shown in **Figure 5C**), with an increase of the protein conjugate peak over time post-dose. These data provide evidence that the in vivo plasma covalent binding also involves albumin.

The recoveries of radioactivity for all plasma samples analyzed by SEC were between 90 and 110%, confirming that the low extraction recoveries for clinical plasma samples were explained by loss of drug related material covalently bound to plasma protein. Correspondingly, the amount of protein-conjugate detected by SEC at each time point was similar to the amount of radioactivity lost on extraction.

Acyl glucuronides are often unstable at neutral pH (Bailey and Dickinson, 2003) but can be stabilized by acidification of clinical samples (Ebner et al., 2010; Wang et al., 2011). As this instability was observed for the AG metabolite in pre-clinical experiments, an aliquot of all plasma and urine samples for analysis of fevipirant and metabolites was acidified by addition of 1% volume of a 70% lactic acid solution. Experiments in blank urine samples showed that a pH in the range of 3.1–5.2 was obtained after acidification (compared with 5.3–7.3 before acidification), and the AG metabolite was confirmed to be stable to hydrolysis for four weeks at

DMD #75358

room temperature in acidified urine (less than 1% degradation to the parent compound measured). However, isomerization of the acyl-glucuronide was not measured here, and may have occurred during the incubation. All clinical data reported here were obtained using the acidified aliquots, except for total radioactivity measurements.

To assess potential acyl-glucuronide isomerization, incubations were performed with a synthesized standard of the 1-O-beta isomer of the AG metabolite to identify other acyl glucuronide isomers formed. Several isomers of the AG metabolite were detected, and were assigned to acyl glucuronide rearrangement products (Bailey and Dickinson, 2003). As these isomers were considered to be degradation products of the AG metabolite that could not be accurately quantified if formed during sample collection or processing, they were quantified together with the AG metabolite for all analyses in this report.

### **Fevipirant as a Substrate of Enzymes and Transporters**

Based on the clinical excretion data, fevipirant clearance pathways include glucuronidation and direct excretion of the parent drug. To determine which enzymes and transporters are involved in these processes, a number of in vitro investigations were carried out, as follows:

For the determination of the enzymes catalyzing the formation of the AG metabolite, in vitro biotransformation of [<sup>14</sup>C]-fevipirant, catalyzed by 12 recombinant uridine 5'-diphospho-glucuronosyltransferase (UDP-glucuronosyltransferase; UGT) enzymes, was investigated. Fevipirant was metabolized by a number of the enzymes (**Table S3** (Supplemental Data)), with UDP-glucuronosyltransferase 1A3 (UGT1A3), UDP-glucuronosyltransferase 2B7 (UGT2B7), and UDP-glucuronosyltransferase 2B17 (UGT2B17) showing the highest activities. Michaelis-Menten enzyme kinetic parameters are shown in **Table 5** and the kinetic profiles are presented in **Figures S3–S5** (Supplemental Data).

DMD #75358

For evaluation of hepatic uptake, [<sup>14</sup>C]-fevipiprant uptake into hepatocytes was measured in the presence and absence of transporter inhibitors. Hepatic uptake clearance was determined to be approximately 10  $\mu\text{L}/\text{min}/10^6$  cells (**Table S4** (Supplemental Data)). Uptake was slower at 4°C or in the presence of organic anion-transporting polypeptide (OATP) transporter inhibitors, indicating a mixture of passive and active (most likely OATP-mediated) hepatic uptake.

For the clarification of transporters involved in hepatic uptake as well as renal, biliary and intestinal secretion, uptake of [<sup>14</sup>C]-fevipiprant into cells overexpressing the corresponding transporters was measured at a range of fevipiprant concentrations in the presence and absence of inhibitors of these transporters. Based on these data (**Figures S6–8** (Supplemental Data)), fevipiprant was determined to be a substrate of transporters OATP1B3 (hepatic uptake;  $K_m = 16 \mu\text{M}$ ), organic anion transporter 3 (OAT3) (renal secretion;  $K_m = 3.2 \mu\text{M}$ ) and multi-drug resistance gene 1 (MDR1) (biliary/intestinal efflux;  $K_m > 200 \mu\text{M}$ , exact value not calculable due to lack of saturation), but not a substrate of transporters OATP1B1, OATP2B1, organic anion transporter 1 (OAT1), organic cation transporter 2 (OCT2), multidrug and toxin extrusion protein 1 (MATE1) or multidrug and toxin extrusion protein 2-K (MATE2-K). This data suggest that fevipiprant is actively taken up into hepatocytes by OATP1B3, and actively excreted into bile and into the GI tract via MDR1 and into urine via OAT3 transport.

DMD #75358

## Discussion

In the present study, the absorption of fevipiprant was estimated to be at least 43.5%, as a minimum estimate based on metabolite excretion and renal fevipiprant excretion. It is likely that the actual absorption value is higher, as AG metabolites would likely hydrolyze to fevipiprant in the gastrointestinal tract after biliary excretion, and in addition direct biliary excretion of fevipiprant is possible. Preclinical data from rat support this hypothesis, with absorption of around 60%, and bile-duct cannulated rat studies after intravenous dosing showing excretion of both fevipiprant (25% of dose) and AG-metabolite (33% of dose) in bile.

The AG metabolite was the only major metabolite detected in plasma. In preclinical species, the AG metabolite was also a major metabolite in plasma and/or excreta, but comprised a lower proportion of total plasma AUC (<30%). However, in toxicity studies exposure to the AG metabolite at the NOAEL was similar or higher than human exposure at the highest phase III dose. The abundance of the AG metabolite was not well predicted from in vitro data. While the AG metabolite was formed in hepatocytes of all species investigated (mouse, rat, dog, monkey, human), the calculated intrinsic clearance was in all cases low (e.g. 0.35  $\mu\text{L}/\text{min}/10^6$  cells in human). It is possible that the in vitro underestimation of metabolic clearance is due to reduced activity of OATP1B3-mediated uptake in cryopreserved hepatocyte suspensions in vitro, in comparison to the in vivo situation where transporters are fully active (Lundquist et al., 2014).

Aside from the AG metabolite, we detected a minor lactone metabolite. Due to its low abundance, the formation of this metabolite was not investigated in more detail. However, several possible formation pathways can be envisaged (see **Figure S9** (Supplemental Data)) involving epoxidation, followed by either nucleophilic ring-closing or epoxide hydrolysis and lactonization. It is unlikely that this possible epoxide intermediate is involved in the formation of

DMD #75358

the observed covalent adduct in plasma, as oxidative covalent binding in microsomes and hepatocytes was negligible (**Table 4**), and relevant reactive metabolites were not detected in plasma.

Total radioactivity was found to decline slowly in blood and plasma after the elimination of the majority of fevipiprant from plasma, likely due to the formation of protein conjugates by covalent binding of the AG metabolite to human serum albumin. The observed terminal half-life of radioactivity in plasma (254 h or 10.6 days) was in the range of, but shorter than, the half-life reported for human albumin (19 days (Peters T., 1995)). Consequently, the terminal half-life of total radioactivity, although calculated using data covering a relatively short time period, is likely to be accurate or somewhat underestimated. Preclinical data in rat and dog show much shorter terminal half-life values for total radioactivity, potentially due to a shorter half-life of albumin in these species (e.g. 2.5 days in rat (Car et al., 2006)). The concentration of radioactivity remaining in plasma after 240 h (500 pmol/mL) corresponds to around 1.5  $\mu$ mol or 0.65 mg fevipiprant equivalent, assuming 3 L human plasma volume. Assuming that approximately 60% of albumin is distributed to extracellular space (Peters T., 1995), the amount of drug-albumin conjugate remaining in the body at 240 hours post-dose is therefore approximately 1.6 mg corresponding to 0.8% of dose (or 0.3% assuming no extra-vascular distribution of the protein conjugate). Given total body albumin of around 360 g (Peters T., 1995), the extent of covalent binding is then around 0.07% of total body albumin. Consequently, repeated dosing with fevipiprant is unlikely to lead to the covalent modification of a large proportion of albumin in the body.

The stability of acyl glucuronides has been previously investigated in detail (Regan et al., 2010). Key factors proposed to be associated with AG stability are steric accessibility and electronic properties of the carboxylic acid/ester functionality. Fevipiprant contains a sterically unhindered carboxylic acid as part of an aryl-acetic acid moiety, similar to diclofenac and tolmetin, which

DMD #75358

also form unstable AG-metabolites (Zia-Amirhosseini et al., 1994; Castillo et al., 1995). It is therefore unsurprising that the AG-metabolite of fevipiprant is also unstable.

Acyl glucuronide-derived drug-protein conjugates have been observed for other drugs such as ibuprofen and tolmetin, as well as bilirubin (Weiss et al., 1983; Zia-Amirhosseini et al., 1994; Castillo et al., 1995), which has been reviewed extensively (Regan et al., 2010). A number of AG-forming drugs have been associated with clinical AEs, such as hepatotoxicity. However, no clear causal link of AEs to the reactivity or covalent protein binding of the AGs has been established. In comparison with other covalent binding compounds (Usui et al., 2009) including compounds that form AG metabolites (Darnell et al., 2015), the in vitro covalent binding of fevipiprant to liver microsomes and hepatocytes (**Table 4**) is negligible. Additionally, no covalent binding to liver microsomes associated with glucuronidation was observed, suggesting that the AG-metabolite does not rapidly bind to liver proteins after its formation. From this it can be inferred that covalent binding to albumin occurs in plasma rather than in the liver, likely due to the high concentrations of both AG metabolite and albumin in plasma.

As of January 2017, over 1700 subjects have been exposed to fevipiprant in the clinical program. Phase 3 trials in asthma are currently ongoing. There have been no AEs of idiopathic drug reactions or liver toxicity in these clinical studies. Overall, the in vivo nonclinical assessments and clinical safety data available to date indicate a low risk of idiosyncratic drug-induced liver injury or other idiosyncratic drug reactions potentially associated with covalent drug-protein binding, in line with the apparently negligible reactive metabolites formed by oxidative pathways.

Excretion and metabolism data from this study indicate that fevipiprant is eliminated by several pathways. Following oral administration, 57% of the dose was detected as unchanged fevipiprant in urine and feces, indicating direct renal and possibly biliary excretion. In addition, 29% of the dose was excreted as metabolites. The exact amounts of dose eliminated by

DMD #75358

metabolism and direct excretion are not clear, as back-conversion of the AG metabolite to fevipiprant during/after excretion is possible. Data from preclinical species (mouse, rat and dog) showed similar excretion routes, except with relatively higher fecal excretion. In mouse, rat and dog, fecal/biliary excretion was around 80% of dose (after both intravenous and oral administration) and renal excretion was 1% in mouse, 6-7% in rat and 11-13% in dog. Urinary excretion in rat and dog consisted mainly of the parent drug, suggesting that the higher overall renal excretion in human is due to a fast renal (rather than biliary) excretion of the AG metabolite, or due to a more extensive formation of AG metabolite in human, in line with the high plasma concentrations of the AG metabolite.

We demonstrated in vitro that fevipiprant was a substrate of several human UDP-glucuronosyltransferases, as well as transporters involved in tubular secretion in the kidney (OAT3), active hepatic uptake (OATP1B3), and biliary excretion (MDR1). The OAT3 data show that the elimination of fevipiprant involves direct renal secretion. This is in line with the measured renal clearance value (~9 L/h), which is higher than the expected glomerular filtration clearance (GFR) (0.9 L/h, based on a GFR of 7.5 L/h (Davies and Morris, 1993) multiplied by the fraction unbound ( $f_u$ ) of fevipiprant (0.118)), as expected in the case of active renal secretion. As fevipiprant is a substrate of MDR1, biliary or intestinal secretion is also likely: this would contribute to the large amount of unchanged fevipiprant excreted in feces. The UGT phenotyping data show that at least three hepatic and extrahepatic (Tukey and Strassburg, 2000) UGT isoenzymes are involved in the metabolic clearance pathways of fevipiprant. Based on the range of elimination pathways and isoenzymes involved in the clearance of fevipiprant, a low risk of DDI or variability due to genetic differences is expected. However, in order to address possible effects of the inhibition of these pathways on the PK of fevipiprant, clinical DDI studies are planned or ongoing with inhibitors of OAT3, UGT enzymes, OATP1B3 and MDR1.



DMD #75358

Additionally, the potential of fevipiprant and its AG-metabolite to inhibit these or other enzymes and transporters involved in drug disposition has been assessed (Barve et al., 2016).

For the AG metabolite, the renal clearance was similar to fevipiprant (~8 L/h) and the expected clearance by glomerular filtration is 1.76 L/h ( $0.234 [fu] \times 125 \text{ mL/min}$ , as described above for fevipiprant). As the expected glomerular filtration clearance is five-fold lower than the observed renal clearance, an active tubular secretion of the AG metabolite is also likely.

In conclusion, we demonstrated that fevipiprant is eliminated via various metabolic enzymes and direct excretion and hence this novel compound is unlikely to be a victim of a strong drug interaction or to display major variability or ethnic sensitivity in PK due to genetic polymorphism. The major metabolite is an acyl glucuronide which forms covalent adducts to albumin in human plasma.

DMD #75358

## **Acknowledgements**

We acknowledge Maxime Garnier, Stephan Utzinger, Claire Adcock, Luu Van Tong, Yves Metz, Matthias Frommherz, Patrick Bross and Hubert Borell for technical assistance and Karine Litherland, David Sandham, Matthias Kittelmann, Ines Rodriguez, Carsten Bauer, Matthew Brown, Albrecht Glaenzel, Walid Elbast, Jagruti Desai, Paul Goldsmith, Ping Zhou and Piet Swart for contribution to study design and execution. Delia Randall provided medical writing and editing support.

DMD #75358

## **Authorship Contributions**

*Participated in research design:* Jin, van Lier, Erpenbeck, End, Glaenzel, Woessner

*Conducted experiments:* van Lier

*Contributed new reagents or analytic tools:* Eggimann

*Performed data analysis:* Pearson, Weiss, Jin, End, Glaenzel

*Wrote or contributed to the writing of the manuscript:* Pearson, Weiss, Jin, Erpenbeck, Glaenzel, End, Eggimann, Camenisch

DMD #75358

## References

- Bailey MJ and Dickinson RG (2003) Acyl glucuronide reactivity in perspective: biological consequences. *Chem Biol Interact* **145**:117-137.
- Bala K, Leblanc C, Sandham DA, Turner KL, Watson SJ, Brown LN, and Cox B (2005) Pyrrolopyridines as CRTh2 receptor antagonists, their preparation, pharmaceutical compositions, and use in therapy, WO2005123731A2.
- Barve A, Tillmann H-C, Ilsley E, Vemula J, Nica A, Imbert G, Elbast W, Schiller H, Camenisch G, and Woessner R (2016) Impact of co-administration of fevipiprant (QAW039) and SLCO1B1 genotype on the PK of simvastatin and rosuvastatin. *European Respiratory Journal* **48**:1108.
- Car BD, Eng VM, Everds NE, and Bounous DI (2006) Chapter 5 - Clinical Pathology of the Rat A2 - Suckow, Mark A, in: *The Laboratory Rat (Second Edition)* (Weisbroth SH and Franklin CL eds), pp 127-146, Academic Press, Burlington.
- Castillo M, Lam YW, Dooley MA, Stahl E, and Smith PC (1995) Disposition and covalent binding of ibuprofen and its acyl glucuronide in the elderly. *Clin Pharmacol Ther* **57**:636-644.
- Darnell M, Breitholtz K, Isin EM, Jurva U, and Weidolf L (2015) Significantly Different Covalent Binding of Oxidative Metabolites, Acyl Glucuronides, and S-Acyl CoA Conjugates Formed from Xenobiotic Carboxylic Acids in Human Liver Microsomes. *Chem Res Toxicol* **28**:886-896.
- Davies B and Morris T (1993) Physiological parameters in laboratory animals and humans. *Pharm Res* **10**:1093-1095.
- Ebner T, Wagner K, and Wiene W (2010) Dabigatran acylglucuronide, the major human metabolite of dabigatran: in vitro formation, stability, and pharmacological activity. *Drug Metab Dispos* **38**:1567-1575.
- EMA (2012) Guideline on the investigation of drug interactions.
- Erpenbeck VJ, Vets E, Gheyle L, Osuntokun W, Larbig M, Neelakantham S, Sandham D, Dubois G, Elbast W, Goldsmith P, and Weiss M (2016) Pharmacokinetics, Safety, and Tolerability of Fevipiprant (QAW039), a Novel CRTh2 Receptor Antagonist: Results From 2 Randomized, Phase 1, Placebo-Controlled Studies in Healthy Volunteers. *Clin Pharmacol Drug Dev* **5**:306-313.
- Evans DC, Watt AP, Nicoll-Griffith DA, and Baillie TA (2004) Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. *Chem Res Toxicol* **17**:3-16.
- FDA (2008) Guidance for industry: safety testing of drug metabolites.
- FDA (2012) Drug Interaction Studies — Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations.

DMD #75358

Gao H, Jacobs A, White RE, Booth BP, and Obach RS (2013) Meeting report: metabolites in safety testing (MIST) symposium-safety assessment of human metabolites: what's REALLY necessary to ascertain exposure coverage in safety tests? *AAPS J* **15**:970-973.

ICH (2009) Guidance on Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals M3 (R2).

ICRP (2007) The 2007 Recommendations of the International Commission on Radiological Protection, in: *Ann ICRP*

Lundquist P, Loof J, Sohlenius-Sternbeck AK, Floby E, Johansson J, Bylund J, Hoogstraate J, Afzelius L, and Andersson TB (2014) The impact of solute carrier (SLC) drug uptake transporter loss in human and rat cryopreserved hepatocytes on clearance predictions. *Drug Metab Dispos* **42**:469-480.

Pawankar R (2014) Allergic diseases and asthma: a global public health concern and a call to action. *World Allergy Organ J* **7**:12.

Peters T. J (1995) Metabolism: Albumin in the Body, in: *All about albumin*, pp 188-250, Academic Press.

Regan SL, Maggs JL, Hammond TG, Lambert C, Williams DP, and Park BK (2010) Acyl glucuronides: the good, the bad and the ugly. *Biopharm Drug Dispos* **31**:367-395.

Sykes DA, Bradley ME, Riddy DM, Willard E, Reilly J, Miah A, Bauer C, Watson SJ, Sandham DA, Dubois G, and Charlton SJ (2016) Fevipiprant (QAW039), a Slowly Dissociating CRTh2 Antagonist with the Potential for Improved Clinical Efficacy. *Mol Pharmacol* **89**:593-605.

Townley RG and Agrawal S (2012) CRTH2 antagonists in the treatment of allergic responses involving TH2 cells, basophils, and eosinophils. *Ann Allergy Asthma Immunol* **109**:365-374.

Tukey RH and Strassburg CP (2000) Human UDP-glucuronosyltransferases: metabolism, expression, and disease. *Annu Rev Pharmacol Toxicol* **40**:581-616.

Usui T, Mise M, Hashizume T, Yabuki M, and Komuro S (2009) Evaluation of the potential for drug-induced liver injury based on in vitro covalent binding to human liver proteins. *Drug Metab Dispos* **37**:2383-2392.

Wang L, Munsick C, Chen S, Bonacorsi S, Cheng PT, Humphreys WG, and Zhang D (2011) Metabolism and disposition of <sup>14</sup>C-labeled peligitazar in humans. *Drug Metab Dispos* **39**:228-238.

Weiss JS, Gautam A, Lauff JJ, Sundberg MW, Jatlow P, Boyer JL, and Seligson D (1983) The clinical importance of a protein-bound fraction of serum bilirubin in patients with hyperbilirubinemia. *N Engl J Med* **309**:147-150.

Xue L, Salimi M, Panse I, Mjosberg JM, McKenzie AN, Spits H, Klenerman P, and Ogg G (2014) Prostaglandin D2 activates group 2 innate lymphoid cells through chemoattractant receptor-homologous molecule expressed on TH2 cells. *J Allergy Clin Immunol* **133**:1184-1194.

DMD #75358

Zia-Amirhosseini P, Ojingwa JC, Spahn-Langguth H, McDonagh AF, and Benet LZ (1994) Enhanced covalent binding of tolmetin to proteins in humans after multiple dosing. *Clin Pharmacol Ther* **55**:21-27.

Zuberbier T, Lotvall J, Simoens S, Subramanian SV, and Church MK (2014) Economic burden of inadequate management of allergic diseases in the European Union: a GA(2) LEN review. *Allergy* **69**:1275-1279.

DMD #75358

## Footnotes

Parts of this work were previously presented at the following conference: Pearson D, Jin Y, Erpenbeck VE, Woessner R, Camenisch G, Weiss HM. Absorption, metabolism and excretion of fevipirant (QAW039) investigated in vivo and in vitro. European Respiratory Society International Congress, 3–7 September, 2016, London, United Kingdom

Address correspondence to: Dr. David Pearson, PK Sciences, Novartis Institutes for Biomedical Research, Postfach, CH-4002 Basel, Switzerland; Tel: +41799112654; Email: [david.pearson@novartis.com](mailto:david.pearson@novartis.com)

DP, MW, YJ, VE, UG, PE, RW, FE and GC are employees of Novartis Pharma and may hold shares in Novartis.

DMD #75358

## Legends for Figures

**Figure 1.** Structural formula of fevipiprant and proposed biotransformation pathways of fevipiprant in humans. \*Position of [<sup>14</sup>C]-radiolabel

**Figure 2.** Plasma concentrations of fevipiprant, AG-metabolite and total radioactivity after oral administration of a 200 mg dose of [<sup>14</sup>C]-fevipiprant to four healthy subjects. Units for fevipiprant and AG-metabolite concentrations are ng/mL, for total radioactivity concentrations ng-eq/mL. Concentrations of fevipiprant and AG metabolite were determined by LC-MS/MS, concentrations of total radioactivity were determined by LSC.

**Figure 3.** Representative radiochromatograms in plasma (3 h post dose), urine (time pooled 0-72 h), and feces extracts (time pooled 0-96 h) for one subject after oral administration of a 200 mg dose of [<sup>14</sup>C]-fevipiprant. dpm: disintegrations per minute

**Figure 4.** Cumulative excretion of radioactivity in urine and feces after oral administration of a 200 mg dose of [<sup>14</sup>C]-fevipiprant to four healthy subjects. Radioactivity was determined by LSC.

### Figure 5.

A) SDS-PAGE analysis of covalent protein binding after 24 h incubation of [<sup>14</sup>C]-AG-metabolite (20 μM) with 1:1 human plasma/PBS at 37 °C. Lanes A1-3: untreated incubation sample; Lanes B1-3: incubation sample after albumin depletion using a ProteoExtract Albumin Removal Kit (Calbiochem). 5, 10, and 20 μg of protein was analysed in lanes A1/B1, A2/B2 and A3/B3, respectively. Protein content was determined using a Protein DC Assay (BioRad). Relative intensities of bands calculated using AIDA software: A1, 5878; A2, 9787; A3, 17839; B1, 2791; B2, 6435; B3, 10635. The molecular weight markers on the left side of the gel were drawn with <sup>3</sup>H-supplemented ink to mark the location of visible marker proteins (all blue standard, BioRad).

B) SEC analysis after 24 h incubation of [<sup>14</sup>C]-AG-metabolite (100 μM) with 1:1 human plasma/PBS at 37 C.



DMD #75358

C) Representative SEC analyses of plasma samples from one healthy subject 2, 6, and 120 h after oral administration of a 200 mg dose of [<sup>14</sup>C]-fevipiprant

DMD #75358

## Tables

**Table 1. PK parameters of total radioactivity in whole blood and plasma and of fevipiprant and its main circulating metabolite (AG metabolite) in plasma (mean ± SD)**

	Total radioactivity in whole blood	Total radioactivity in plasma	Fevipiprant in plasma	AG metabolite in plasma
<b>T<sub>max</sub></b> (h) <sup>a)</sup>	3.00 (3.00–6.00)	3.00 (3.00–6.00)	2.50 (2.00–6.00)	3.00 (3.00–6.00)
<b>C<sub>max</sub></b> (ng/mL or ng-eq/mL) <sup>b)</sup>	923 ± 216	1750 ± 396	348 ± 139	1450 ± 353
<b>AUC<sub>0–240 h</sub></b> (ng*h/mL or ng- eq*h/mL) <sup>c)</sup>	36400 ± 6960	76500 ± 9740	2490 ± 312	9840 ± 1770
<b>AUC<sub>inf</sub></b> (ng- eq*h/mL)	69700 ± 10600	156000 ± 20700	-	-
<b>CL/F</b> (L/h)	-	-	80.5 ± 9.42	-
<b>Vz/F</b> (L)	-	-	1370 ± 459	-
<b>T<sub>1/2</sub></b> (h)	230 ± 54.6	254 ± 24.8	12.3 ± 5.95	11.8 ± 5.19

<sup>a)</sup>T<sub>max</sub> is presented as median (range). <sup>b)</sup> ng/mL for fevipiprant and AG-metabolite, ng-eq/mL for total radioactivity. <sup>c)</sup> ng\*h/mL for fevipiprant and AG-metabolite, ng-eq\*h/mL for total radioactivity.

DMD #75358

**Table 2. Fevipiprant and metabolites in plasma, based on metabolism profiles (mean ± SD)**

Component	<sup>14</sup> C]-AUC <sub>0-12 h</sub> <sup>a)</sup>	
	ng/mL or ng- eq*h/mL <sup>b)</sup>	% of total
<b>Fevipiprant</b>	1690 ± 266	15.3 ± 2.33
<b>AG metabolite</b>	6240 ± 922	56.5 ± 5.65
<b>P8.5</b>	125 ± 145	1.18 ± 1.37
<b>Sum of additional components</b>	47.1 ± 52.9	0.405 ± 0.426
<b>Total components detected</b>	8100 ± 852	73.4 ± 2.73
<b>Lost during sample processing</b>	2920 ± 210	26.6 ± 2.73
<b>Total radiolabeled components in sample</b>	11000 ± 837	100

<sup>a)</sup>Calculated using the linear trapezoidal method; concentrations at time zero taken as zero. <sup>b)</sup> ng/mL for fevipiprant, ng-eq/mL for other components.

DMD #75358

**Table 3. Fevipiprant and metabolites in excreta (mean ± SD)**

Component	Excretion (% of dose) <sup>a)</sup>			Excretion
	Urine	Feces	Total	(% of dose) <sup>b)</sup>
	0–72 h	0–96 h		Urine 0–240 h
<b>Fevipiprant</b>	12.7 ± 2.21	44.5 ± 6.12	57.2 ± 6.29	11.0 ± 1.56
<b>AG metabolite</b>	26.9 ± 2.58	1.24 ± 0.244	28.1 ± 2.40	27.6 ± 3.53
<b>Lactone metabolite</b>	0.133 ± 0.0458	0.177 ± 0.355	0.310 ± 0.389	n/a
<b>P5.3</b>	0.0956 ± 0.0121	0.00	0.0956 ± 0.0121	n/a
<b>Total components detected</b>	39.8 ± 3.35	46.0 ± 6.36	85.7 ± 5.16	n/a
<b>Total excretion in time period<sup>c)</sup></b>	41.2 ± 3.78	50.5 ± 6.26	91.7 ± 4.97	n/a

<sup>a)</sup>Quantified from radioactivity profiles; <sup>b)</sup>Quantified by LC-MS/MS; <sup>c)</sup>The difference between total excretion and total components detected corresponds to losses during sample preparation.

DMD #75358

**Table 4. Covalent binding of fevipiprant to microsomes and hepatocytes in vitro**

<b>Incubation conditions</b>	<b>Amount of covalent drug protein adducts</b>
<b>HLM, GSH</b>	1 ± 0.0 pmol/mg protein
<b>HLM, NADPH</b>	3 ± 0.4 pmol/mg protein
<b>HLM, NADPH, UDPGA</b>	3 ± 0.3 pmol/mg protein
<b>HLM, NADPH, UDPGA, GSH</b>	1 ± 0.5 pmol/mg protein
<b>HH</b>	8 ± 1.4 pmol/10 <sup>6</sup> cells

HLM: human liver microsomes; HH: human hepatocytes; GSH: glutathione; NADPH: nicotine adenine dinucleotide phosphate; UDPGA: uridine diphosphoglucuronic acid.

DMD #75358

**Table 5. Michaelis-Menten enzyme kinetic parameters for biotransformation of fevipiprant by UGT enzymes.**

	UGT1A3	UGT2B7	UGT2B17
$V_{\max}$ (mean $\pm$ SD, pmol/min/mg)	5634 $\pm$ 1603	35.2 $\pm$ 6.8	43.3 $\pm$ 0.9
$K_m$ (mean $\pm$ SD, $\mu$ M)	13352 $\pm$ 5854	320 $\pm$ 143	53.3 $\pm$ 4.5
Derived intrinsic clearance ( $V_{\max}/K_m$ , $\mu$ L/mg/min)	0.422	0.11	0.812

DMD #75358

## Figures




Figure 1

DMD #75358




Figure 2



DMD #75358




Figure 3

DMD #75358






Figure 4

DMD #75358

**A**



**B**



**C**




Figure 5